XOMA Corporation (XOMA) Earns Daily News Impact Score of 0.08
Media coverage about XOMA Corporation (NASDAQ:XOMA) has trended somewhat positive on Saturday, Accern reports. Accern rates the sentiment of media coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. XOMA Corporation earned a coverage optimism score of 0.08 on Accern’s scale. Accern also assigned headlines about the biotechnology company an impact score of 46.5604136216606 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
These are some of the headlines that may have impacted Accern’s scoring:
- Critical Contrast: XOMA Corporation (XOMA) & Its Rivals (americanbankingnews.com)
- Financial Comparison: XOMA Corporation (XOMA) and Its Peers (americanbankingnews.com)
- Allergan plc (AGN) has a value of $208.39 per share While XOMA Corporation (XOMA) is stand at $20.69 – Stocks Gallery (stocksgallery.com)
- XOMA Announces Multiple New License Agreements for Proprietary Phage Display Libraries – GlobeNewswire (press release) (globenewswire.com)
Shares of XOMA Corporation (NASDAQ:XOMA) traded up 0.52% on Friday, hitting $21.23. The stock had a trading volume of 85,549 shares. XOMA Corporation has a one year low of $3.96 and a one year high of $22.69. The company’s market cap is $161.31 million. The firm’s 50-day moving average is $16.21 and its 200-day moving average is $9.18.
Several brokerages have recently weighed in on XOMA. Zacks Investment Research downgraded XOMA Corporation from a “hold” rating to a “sell” rating in a research note on Tuesday, September 26th. Wedbush raised XOMA Corporation from a “neutral” rating to an “outperform” rating and upped their target price for the stock from $9.00 to $19.00 in a research note on Tuesday, September 5th. HC Wainwright reaffirmed a “buy” rating and set a $15.00 target price on shares of XOMA Corporation in a research note on Thursday, August 10th. Finally, ValuEngine raised XOMA Corporation from a “strong sell” rating to a “sell” rating in a research note on Wednesday, July 12th. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating and two have issued a buy rating to the stock. XOMA Corporation currently has an average rating of “Hold” and a consensus price target of $14.00.
About XOMA Corporation
XOMA Corporation is a development-stage biotechnology company. The Company focuses on the discovery and development of monoclonal antibody-based therapeutics. It has five products in its endocrine portfolio, two of which are developed as part of its XOMA Metabolism (XMet) platform. Its products include XOMA 358, XOMA 129, XOMA 213 and Gevokizumab.
Receive News & Ratings for XOMA Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XOMA Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.